← Home / REGENERON PHARMACEUTICALS, INC. (REGN)
Stock Analysis
REGENERON PHARMACEUTICALS, INC. (REGN)
REGN
REGN · Healthcare • Biotech
678.09 +0.21%
Track REGN in your personal workspace Monitor performance, SPY relative strength and WOI View from your watchlist.
Alert me when REGN price is:
52W Range Position
50%
LOWMIDHIGH
Trend
Mixed
Momentum
Neutral
Updated: 2026-07-20 16:28 UTC
WOI Investment Thesis
Mixed
Confirmation improves above 688.63. Holding above 659.01 keeps the current thesis intact.
⚖️
✓
Fundamentals
Moderate / Positive
✓
Price Structure
Mixed
•
Momentum
Neutral
×
Breakout Confirmation
Pending
Risk Level
Elevated
Analysis Scope
1Y Daily
Key Decision Levels
✓
Hold Above
Structure remains valid above support.
659.01
↗
Break Above
Confirmation improves above resistance.
688.63
🎯
Next Objective
Pattern-derived target if setup continues.
738.98
×
Thesis Break
Scenario weakens below invalidation.
Below 659.01
What's Driving REGN?
📈 Technical recovery is improving
Momentum is Neutral. Watch 688.63 for confirmation and 659.01 for structure risk.
💼 Business quality remains relevant
Fundamentals remain relevant. Check growth, profitability, cash flow and balance sheet quality.
⚠️ Key risk remains
Below 659.01
Full Analysis Workspace
Technical Signal
Technical Setup Active
✓
An active technical structure is present. Use trigger, target, stop and watch levels for context.
Pattern
Bull Flag · Confirmed
Trigger
668.61
Target
738.98
Invalidation
637.72
RSI(14)
62.5
◎
How to read this setup
The next meaningful technical decision is likely to occur between support at 659.01 and resistance at 688.53. A cleaner push through resistance would improve continuation odds, while a loss of support would weaken the current thesis. Pattern invalidation sits near 573.77, so a violation there would materially change the current setup narrative.
Price Chart
REGN · WOI overlay chart
Open Full Workspace
Valuation Snapshot (TTM)
Full valuation · Ratios use trailing twelve months
Updated 2026-07-17
Support
Cash-flow supported
Earnings multiple and free-cash-flow yield look supportive.
Market Cap
$63.9B
Company size
EV
$65.1B
Debt-adjusted value
P/E
14.4
Low multiple
P/S
4.3
Balanced
P/B
2.0
Balanced
EV/Sales
4.4
Balanced
EV/EBIT
17.9
Low multiple
P/FCF
13.4
Low multiple
FCF Yield
7.48%
Cash return
Source: SEC TTM data via WOI valuation cache Not financial advice
Business Lens
Improving financial execution
Financial conditions require selective monitoring.
↗
Revenue Growth
Moderate
●
Profitability
Positive
≈
Cash Flow
Positive
⚖
Balance Sheet
Strong
💵 Revenue
3.61B
≈ Moderate
📈 Net Income
727.20M
↗ Positive
🧮 EPS (Basic)
6.99
↗ Positive
REGENERON PHARMACEUTICALS, INC.
Healthcare • Biotech
Related Opportunities